Zogenix, Inc.
Pharmaceutical ManufacturingCalifornia, United States201-500 Employees
On March 7, 2022, Zogenix, Inc. was acquired by UCB. For more information, please visit www.linkedin.com/company/ucb-pharma.
Strategic Acquisition Since being acquired by UCB in March 2022, Zogenix has benefited from increased investment and integration into a larger pharmaceutical group, opening opportunities to collaborate on advanced drug development, manufacturing, and supply chain solutions.
Expansion Investments UCB's substantial investments in expanding manufacturing facilities in Switzerland and the United States, including a $5 billion factory in the US and a $125 million biopharmaceutical site in Switzerland, indicate ongoing growth and require related technological and operational support.
Sustainability Leadership Recognition as one of the world's most sustainable companies in 2025 positions UCB as a strategic partner for eco-conscious pharmaceutical initiatives, opening doors for sustainable technology and environmentally friendly supply chain solutions.
Workforce Growth UCB's plans to increase headcount by 380 employees in recent projects, including new biologics manufacturing facilities, suggests opportunities to provide HR, training, and technology solutions tailored to large-scale pharma talent development.
Technological Ecosystem The adoption of various advanced tech tools such as Power BI, ISO standards, and TypeScript reflects a commitment to digital transformation, creating potential for supporting or enhancing these systems through data analytics, compliance, and software solutions.
Zogenix, Inc. uses 8 technology products and services including Canva, Power BI, ISO 13485, and more. Explore Zogenix, Inc.'s tech stack below.
| Zogenix, Inc. Email Formats | Percentage |
| FLast@zogenix.com | 78% |
| First.Last@zogenix.com | 5% |
| LastFir@zogenix.com | 2% |
| Last_First@zogenix.com | 2% |
| First_Last@zogenix.com | 1% |
| Last@zogenix.com | 1% |
| Last.First@zogenix.com | 1% |
| LastFirst@zogenix.com | 2% |
| FirstLas@zogenix.com | 1% |
| FirstLast@zogenix.com | 1% |
| FMiddleLast@zogenix.com | 1% |
| FiLast@zogenix.com | 1% |
| F.Last@zogenix.com | 1% |
| Last.F@zogenix.com | 1% |
| FirstLa@zogenix.com | 1% |
| First_L@zogenix.com | 1% |
| First.Last@ucb.com | 93% |
| FLast@ucb.com | 5% |
| First@ucb.com | 1% |
| Last.First@ucb.com | 1% |
Pharmaceutical ManufacturingCalifornia, United States201-500 Employees
On March 7, 2022, Zogenix, Inc. was acquired by UCB. For more information, please visit www.linkedin.com/company/ucb-pharma.
Zogenix, Inc. has raised a total of $230M of funding over 16 rounds. Their latest funding round was raised on Sep 22, 2020 in the amount of $230M.
Zogenix, Inc.'s revenue is estimated to be in the range of $25M$50M
Zogenix, Inc. has raised a total of $230M of funding over 16 rounds. Their latest funding round was raised on Sep 22, 2020 in the amount of $230M.
Zogenix, Inc.'s revenue is estimated to be in the range of $25M$50M